👤 Yuichiro Doki

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
2
Articles
2
Name variants
Also published as: Noriko Doki,
articles
Machiko Kawamura, Daichi Sadato, Masayuki Haruta +8 more · 2026 · EJHaem · Wiley · added 2026-04-24
We report an adolescent This case illustrates that therapy-resistant The authors have confirmed clinical trial registration is not needed for this submission.
📄 PDF DOI: 10.1002/jha2.70217
MLLT10
Masaru Sasaki, Norikatsu Miyoshi, Shiki Fujino +11 more · 2021 · Cancer letters · Elsevier · added 2026-04-24
Chromosome instability is one of the hallmarks of cancer. Stromal antigen (STAG) 3 is a core component of the meiosis-specific cohesin complex, which regulates sister chromatid cohesion. Although aber Show more
Chromosome instability is one of the hallmarks of cancer. Stromal antigen (STAG) 3 is a core component of the meiosis-specific cohesin complex, which regulates sister chromatid cohesion. Although aberrantly activated genes encoding the cohesin complex have been identified in cancers, little is known about the role of STAG3 in colorectal cancer (CRC). Here, we evaluated the prognostic impact and role of STAG3 in CRC. Analysis of 172 CRC surgical specimens revealed that high STAG3 expression was associated with poor prognosis. STAG3 knockdown inhibited cell migration and increased drug sensitivity to oxaliplatin, 5-fluorouracil, irinotecan hydrochloride hydrate, and BRAF inhibitor in CRC cell lines. The enhanced drug sensitivity was also confirmed in a human organoid established from a CRC specimen. Moreover, suppression of STAG3 increased γH2AX foci. Particularly, in BRAF-mutant CRC cells, STAG3 silencing suppressed the expression of snail family transcriptional repressor 1 and phosphorylation of extracellular signal-regulated kinase via upregulation of dual-specificity phosphatase 6. Our findings suggest that STAG3 is related to poor clinical outcomes and promotes metastasis and chemotherapeutic resistance in CRC. STAG3 may be a novel prognostic marker and potential therapeutic target for CRC. Show less
no PDF DOI: 10.1016/j.canlet.2020.10.006
DUSP6